LitAlert ~~ GeneLit.com

    • Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Jun 1.

    Drug Approval: FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer (U.S. Food & Drug Administration)

    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 May 21:S1879-8500(20)30099-0. doi: 10.1016/j.prro.2020.04.003. Epub ahead of print.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.